CHRONIC MIGRAINE
Consider limitations of Long-Term Extension study design when interpreting efficacy results.
Patients randomized to quarterly dosing had a mean baseline of 13.2 headache days of at least moderate severity per month and experienced, on average1:
4.7 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).2
Patients randomized to monthly dosing had a mean baseline of 12.8 headache days of at least moderate severity per month and experienced, on average1:
5.1 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).2
*Reduction in monthly average number of headache days from the Long-Term Extension study was 6.8 with monthly dosing.2